🕒 Last update: loading…

Stock Regencell Bioscience Holdings Limited RGC

Regencell Bioscience Holdings Limited — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ✅ Price trend passed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2021 → 2022: -12.43%

Price change 2022 → 2023: -62.35%

Price change 2023 → 2024: -52.95%

Price change 2024 → 2025: 16053.85%

Price change 2025 → 2026: -70.57%

Price change 2026 (year to date): -69.91%

Financial growth

Revenue CAGR (7 years): N/A

Earnings CAGR (7 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.11

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -682.00

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 81.67% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Regencell Bioscience Holdings Limited–0.11–🔒
Clover Health Investments, Corp.113.00.00+31.6 %–
Pediatrix Medical Group, Inc.14.00.76+2.1 %–
Addus HomeCare Corporation18.60.19+11.7 %★ 4/5
iRhythm Technologies, Inc.–4.79+38.2 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Accounts and financial health

Balance sheet and cash flow published by Regencell Bioscience Holdings Limited over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
1,103.47
safe zone (above 2.99)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
1.23 x
moderate debt
Fiscal year20222023202420252026
Cash and investments16.4 m11.6 m8.0 m4.9 m14.2 m
Total Debt771,255463,66985,741544,415295,811
Net Debt-5.6 m-1.1 m-2.9 m-1.9 m-13.9 m
Equity17.1 m12.0 m8.2 m4.9 m13.3 m
Total assets18.0 m12.6 m8.4 m5.8 m14.7 m
Operating cash flow-5.3 m-5.0 m-4.0 m-3.1 m-7.7 m
Investments (capex)780,87627,3925,376152,6890
Free cash-flow-6.0 m-5.0 m-4.0 m-3.3 m-7.7 m
Share buybacks00001.8 m
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-217.16 x
Price / book value189.92 x
Return on Equity (ROE)-160.6 %
Return on Invested Capital (ROIC)-85.9 %
Net margin0.0 %
Debt / equity0.02 x
Current ratio10.77 x
Free cash-flow yield-0.3 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 16/07/2021
ISIN code
KYG7487R1002
Workforce
12
full-time employees
Chief executive
Yat-Gai Au

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Regencell Bioscience Holdings Limited

What is the Regencell Bioscience Holdings Limited share price?

Latest recorded price: 4.94 USD on 13/11/2026, for a market cap of 2.4 bn USD.

Is Regencell Bioscience Holdings Limited stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN KYG7487R1002).

How many employees does Regencell Bioscience Holdings Limited have?

12 full-time employees according to the latest published profile.

Who runs Regencell Bioscience Holdings Limited?

Yat-Gai Au is the company's chief executive.

07

Similar stocks